Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Agenus Inc (NQ: AGEN ) 5.170 +0.140 (+2.78%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Agenus Inc < Previous 1 2 3 4 Next > Shareholder Rights Law Firm Robbins LLP Reminds AGEN Stockholders with Large Losses They Should Obtain Counsel to Seek Lead Plaintiff Status in the Agenus Inc. Class Action Lawsuit September 25, 2024 From Robbins LLP Via Business Wire ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN September 23, 2024 From The Rosen Law Firm PA Via GlobeNewswire AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline September 23, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, New Fortress, and ZoomInfo and Encourages Investors to Contact the Firm September 22, 2024 From Bragar Eagel & Squire Via GlobeNewswire AGEN Class Action Notice: Robbins LLP Reminds Agenus Inc. Stockholders of Pending AGEN Class Action Lawsuit September 20, 2024 From Robbins LLP Via GlobeNewswire AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! September 20, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire ROSEN, A LEADING LAW FIRM, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN September 20, 2024 From The Rosen Law Firm PA Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, and ZoomInfo and Encourages Investors to Contact the Firm September 18, 2024 From Bragar Eagel & Squire Via GlobeNewswire Agenus Inc. Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the AGEN Class Action Lawsuit September 17, 2024 From Robbins LLP Via Business Wire ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN September 16, 2024 From The Rosen Law Firm PA Via GlobeNewswire AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline September 16, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, and ZoomInfo and Encourages Investors to Contact the Firm September 14, 2024 From Bragar Eagel & Squire Via GlobeNewswire Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 September 13, 2024 From Agenus Inc. Via Business Wire AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! September 12, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire AGENUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Agenus Inc. and Encourages Investors to Contact the Firm September 11, 2024 From Bragar Eagel & Squire Via GlobeNewswire Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Agenus Inc. September 10, 2024 From Robbins LLP Via GlobeNewswire AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit with the Schall Law Firm September 09, 2024 From The Schall Law Firm Via Business Wire Rosen Law Firm Urges Agenus Inc. (NASDAQ: AGEN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights September 09, 2024 From The Rosen Law Firm, P.A. Via Business Wire AGENUS INC. (NASDAQ: AGEN) INVESTOR ALERT: Investors With Large Losses in Agenus Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights September 09, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 September 09, 2024 From Agenus Inc. Via Business Wire Agenus to Participate in September Investor Conferences September 03, 2024 From Agenus Inc. Via Business Wire Agenus Reports Second Quarter 2024 Operational and Financial Results August 08, 2024 From Agenus Inc. Via Business Wire Agenus Announces Appointment of Tom Harrison to Board of Directors August 08, 2024 From Agenus Inc. Via Business Wire Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers August 07, 2024 From Agenus Inc. Via Business Wire Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update July 26, 2024 From Agenus Inc. Via Business Wire AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm July 18, 2024 From Schall Law Firm Via Business Wire Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer July 18, 2024 From Agenus Inc. Via Business Wire Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference June 28, 2024 From Agenus Inc. Via Business Wire Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies June 27, 2024 From Agenus Inc. Via Business Wire Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors June 17, 2024 From Agenus Inc. Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.